JP2018524393A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524393A5
JP2018524393A5 JP2018503747A JP2018503747A JP2018524393A5 JP 2018524393 A5 JP2018524393 A5 JP 2018524393A5 JP 2018503747 A JP2018503747 A JP 2018503747A JP 2018503747 A JP2018503747 A JP 2018503747A JP 2018524393 A5 JP2018524393 A5 JP 2018524393A5
Authority
JP
Japan
Prior art keywords
polypeptide
adenovirus
antigen
seq
related antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018503747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524393A (ja
Filing date
Publication date
Priority claimed from GBGB1513176.6A external-priority patent/GB201513176D0/en
Application filed filed Critical
Publication of JP2018524393A publication Critical patent/JP2018524393A/ja
Publication of JP2018524393A5 publication Critical patent/JP2018524393A5/ja
Pending legal-status Critical Current

Links

JP2018503747A 2015-07-27 2016-07-25 免疫応答を誘導するための新規方法 Pending JP2018524393A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1513176.6A GB201513176D0 (en) 2015-07-27 2015-07-27 Novel methods for inducing an immune response
GB1513176.6 2015-07-27
PCT/EP2016/067622 WO2017017050A1 (en) 2015-07-27 2016-07-25 Novel methods for inducing an immune response

Publications (2)

Publication Number Publication Date
JP2018524393A JP2018524393A (ja) 2018-08-30
JP2018524393A5 true JP2018524393A5 (cg-RX-API-DMAC7.html) 2019-09-05

Family

ID=54106649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018504131A Pending JP2018521666A (ja) 2015-07-27 2016-07-25 新規アデノウイルス
JP2018503747A Pending JP2018524393A (ja) 2015-07-27 2016-07-25 免疫応答を誘導するための新規方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018504131A Pending JP2018521666A (ja) 2015-07-27 2016-07-25 新規アデノウイルス

Country Status (15)

Country Link
US (4) US20180216081A1 (cg-RX-API-DMAC7.html)
EP (2) EP3328420A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018521666A (cg-RX-API-DMAC7.html)
KR (1) KR20180034589A (cg-RX-API-DMAC7.html)
CN (2) CN108135991A (cg-RX-API-DMAC7.html)
AR (1) AR105470A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016301029B2 (cg-RX-API-DMAC7.html)
BE (2) BE1023916A9 (cg-RX-API-DMAC7.html)
BR (2) BR112018001572A2 (cg-RX-API-DMAC7.html)
CA (2) CA2993371A1 (cg-RX-API-DMAC7.html)
EA (1) EA201890355A1 (cg-RX-API-DMAC7.html)
GB (1) GB201513176D0 (cg-RX-API-DMAC7.html)
IL (1) IL257071A (cg-RX-API-DMAC7.html)
MX (2) MX2018001215A (cg-RX-API-DMAC7.html)
WO (2) WO2017017049A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR20180112024A (ko) 2016-02-23 2018-10-11 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
DK3436591T5 (da) * 2016-03-31 2024-09-16 The European Molecular Biology Laboratory Adenovirale coat-protein-afledte transportvehikler
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3697919A1 (en) 2017-10-16 2020-08-26 GlaxoSmithKline Biologicals SA Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
CN111479926A (zh) * 2017-10-16 2020-07-31 葛兰素史密丝克莱恩生物有限公司 具有两个表达盒的猿猴腺病毒载体
CN111655847A (zh) * 2017-10-16 2020-09-11 葛兰素史密丝克莱恩生物有限公司 能够复制的腺病毒载体
BR112020007042A2 (pt) * 2017-10-16 2020-11-17 Glaxosmithkline Biologicals S.A. promotor intensificado
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
AU2019251356B2 (en) 2018-04-09 2025-06-12 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
WO2019239311A1 (en) * 2018-06-12 2019-12-19 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2020033876A1 (en) 2018-08-10 2020-02-13 Nantbio, Inc. Cellular adjuvants for viral infection
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用
CN110606875A (zh) * 2019-09-20 2019-12-24 中国农业科学院兰州兽医研究所 一种用于制备口蹄疫疫苗的分子内佐剂及其应用和口蹄疫疫苗
WO2021067448A1 (en) * 2019-09-30 2021-04-08 Applied Genetic Technologies Corporation Adeno-associated virus (aav) systems for treatment of genetic hearing loss
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN113088538A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd3型腺病毒的表达载体及其构建方法
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN114438128A (zh) * 2020-10-30 2022-05-06 上海市公共卫生临床中心 一种增强型溶瘤腺病毒及其应用
US20240033334A1 (en) * 2020-12-04 2024-02-01 Gritstone Bio, Inc. Compositions and methods of use thereof
JP2024534178A (ja) * 2021-08-31 2024-09-18 ヴィア・バイオテクノロジー・インコーポレイテッド 結核ワクチン
CN118662620A (zh) * 2023-03-15 2024-09-20 康希诺生物股份公司 一种肺结核疫苗及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ319377A (en) 1995-09-01 2000-01-28 Corixa Corp polypeptides comprising a portion of a soluble M tuberculosis antigen
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
AU2001268678B2 (en) * 2000-06-20 2006-11-16 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2003213118A1 (en) * 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
CA2993042A1 (en) * 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
ES2442225T3 (es) 2004-04-28 2014-02-10 The Trustees Of The University Of Pennsylvania Régimen de inmunización con cebado de adenovirus suprimido en E4 y potenciación de adenovirus suprimido en E1
JP5164830B2 (ja) * 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
AU2006257323B2 (en) 2005-06-17 2011-12-22 Msd Italia S.R.L. Hepatitis C virus nucleic acid vaccine
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
WO2009105084A2 (en) * 2007-11-28 2009-08-27 The Trustees Of The University Of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP3385387B1 (en) * 2009-02-02 2021-08-25 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
US8932600B2 (en) * 2010-01-27 2015-01-13 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
TR201902214T4 (tr) * 2010-04-16 2019-03-21 Glaxosmithkline Biologicals Sa Şempanze adenoviral vektörü-bazlı filovirüs aşıları.
PT3023106T (pt) * 2010-12-14 2019-11-04 Glaxosmithkline Biologicals Sa Composição antigénica de micobactéria
WO2013123579A1 (en) * 2012-02-24 2013-08-29 Mcmaster University Adenovirus-based tuberculosis vaccine and its use
BE1024420B1 (fr) 2015-06-12 2018-02-19 Glaxosmithkline Biologicals Sa Polynucleotides et polypeptides d'adenovirus

Similar Documents

Publication Publication Date Title
JP2018524393A5 (cg-RX-API-DMAC7.html)
CN102666575B (zh) 分枝杆菌疫苗
JP5555431B2 (ja) 自己免疫疾患を予防し治療するための物質
JP2008530245A5 (cg-RX-API-DMAC7.html)
JP2014527404A5 (cg-RX-API-DMAC7.html)
JP2018513678A5 (cg-RX-API-DMAC7.html)
JP2020528911A5 (cg-RX-API-DMAC7.html)
EP1490101A1 (en) Methods of enhancing immune induction involving mda-7
US20250223320A1 (en) Hepatitis b vaccines and uses of the same
CN111741766A (zh) 用于诱导针对乙型肝炎病毒(hbv)的免疫应答的方法和组合物
KR20230113331A (ko) 인간 파필로마 바이러스 백신 및 hpv 연관된 질환에 대한 이의 용도
US20220226459A1 (en) Dosage regimens for vaccines
US9676825B2 (en) Chimeric vaccine antigens against hepatitis C virus
Basirnejad et al. Development of HCV therapeutic vaccines using Hp91 peptide and small heat shock protein 20 as an adjuvant
JP2025504364A (ja) 慢性b型肝炎感染症を処置または防止するための複数抗原治療ワクチン
US20210290753A1 (en) Crimean-congo hemorrhagic fever virus immunogenic compositions
JPWO2022187424A5 (cg-RX-API-DMAC7.html)
US11097001B1 (en) Composition and method against tuberculosis
RU2024104848A (ru) Рекомбинантный антиген для индукции иммунного ответа против вируса зика
RU2023124900A (ru) Композиции, содержащие адъюванты sbi, и способы их применения
KR20220145736A (ko) 코로나바이러스감염증 예방용 백신의 투여 및 용량
US20190276502A1 (en) Fusion polypeptides derived from staphylococcus aureus antigens
JP2014505700A (ja) 抗原性gly1ポリペプチド